BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark: 2025 Achievements & 2026 Vision
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
BioMark Diagnostics using biomarkers for early cancer detection to save lives, healthcare resources
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
BioMark Announces the Final Closing of Oversubscribed Private Placement
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025
BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York
The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference
BioMark Announces Warrant Extension and Granting of Options
BioMark to Advance Development of Cancer Treatment for Glioblastoma
BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities
Theresa Peterson Joins Biomark's Advisory Team
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update
BioMark to Present New Cancer Screening Data Using the LDTD-MS/MS Technique at the Annual ASMS Conference on Mass Spectrometry
Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
BioMark Announces Change of Auditor
Biomark to Open a Diagnostic Laboratory in Quebec
BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
BioMark Grants Options
BioMark and Phytronix Technologies Inc. Enter into a Collaborative Research and Development Agreement
BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform